Evidence of transmission of an NDM-5-producing Klebsiella pneumoniae in a healthcare facility in New Zealand 2 In NZ to date, the majority of patients with CPE have had a history of hospitalization or travel within countries with a high prevalence of CPE. However, for the first time in 2015, transmission of CPE in NZ healthcare facilities was identified. 2 There were two such events, one of which was in our hospital. Here, we describe that event, which involved four patients with the same strain of Klebsiella pneumoniae with bla NDM-5 .
The first isolate was identified in a faecal sample, sent from a haematology patient for routine screening for MDR organisms, ESBL, CPE, MRSA and VRE, in September 2015. Our hospital infection policy states that haematology inpatients are screened on admission for ESBL, CPE, VRE and MRSA and subsequently on a weekly basis for ESBL, CPE and VRE. Over the next 3 weeks a further two cases were identified. An outbreak was declared and screening of close hospital contacts was undertaken. This screening identified one further case who was also a haematology patient. The patient characteristics are presented in Table 1 . The index case had travelled as a tourist to the UK via a short stopover in Singapore 2 years prior. He had visited a UK general practitioner (GP) on one occasion but had not been hospitalized. The other cases had no recent travel history or hospitalization abroad. The organism was isolated from screening samples from three cases and a catheter urine sample from the remaining case. All cases were considered to be colonized rather than infected. The patients were aged between 48 and 85 years, had significant comorbidities and all had previously received broad-spectrum antibiotics. Epidemiological investigation was unable to discover the exact mechanism of transmission between the four patients as there were no identifiable common links between the four apart from being hospital inpatients. The inpatient stays of the two haematology patients did not overlap, although they had stayed in the same multi-bedded room in non-adjoining bed spaces 10 days apart on the haematology unit. No lapse in infection control procedures was identified. All had radiological investigations as inpatients but no opportunity for cross-transmission was identified. No environmental testing was carried out. There have been no further cases at the time of writing.
All isolates were identified as K. pneumoniae by MALDI-TOF (Bruker Daltonics) and had the same susceptibility pattern: resistant to all b-lactams (including aztreonam), gentamicin, fosfomycin and tigecycline, and susceptible only to amikacin and colistin. Modified Hodge test, Rosco testing and in-house CarbaNP testing showed the isolates were likely metallo-b-lactamase (MBL) producers. The isolates were referred to the ESR national reference laboratory for further testing, including WGS. Genomic DNA was extracted using the High Pure PCR template preparation kit (Roche), DNA libraries were created using the Nextera XT DNA preparation kit (Illumina) and sequencing was performed on the MiSeq platform (Illumina) with 2 by 150 bp paired-end chemistry. WGS showed that all four isolates harboured bla NDM-5 , bla TEM-1B and bla CTX-M-3 . The multilocus STs were derived in silico, and the four isolates were the same novel type, which was assigned as ST2266. An SNP analysis of the core genome showed there were 28 SNP differences between the four isolates. The isolates were also indistinguishable by PFGE after digestion with XbaI. The finding of the bla CTX-M-3 ESBL gene along with bla NDM-5 in these isolates is unusual and has not been observed among CPE in NZ before, and, as far as we are aware, has not been reported in the literature. The combination of bla CTX-M-3 and bla NDM-1 has been reported in a Klebsiella oxytoca isolate from a pelvic aspirate in Taiwan and in a K. pneumoniae isolate from a blood culture in central China, with the latter isolate also harbouring bla KPC-2 .
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The NDM-5 carbapenemase gene was first isolated in an Escherichia coli ST648 isolate in the UK in 2011 in a patient who had received hospital-based inpatient care in India. 5 Since then, there have been published reports of isolates of NDM-5-producing K. pneumoniae in a small number of countries, including South Korea, Singapore, Denmark and the Netherlands. [6] [7] [8] [9] Recent reports from China have shown that NDM-5 appears to be spreading within Enterobacteriaceae, with a recent publication detailing spread of NDM-5 to Proteus mirabilis via IncX3 plasmids. 10 This is the first known published report of transmission of an NDM-producing organism in an NZ healthcare facility as well as being the first known published report of K. pneumoniae ST2266. Although the number of cases is rising, NZ is still a relatively lowincidence country for CPE. There is, however, a need to raise general awareness of the risk factors associated with CPE carriage and infection, to have nationally consistent screening policies and infection control practices, and to ensure that laboratories are using methods capable of detecting CPE.
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